Definition and Classification of Retinal Vein Occlusion

Kolář, Petr

doi:10.17554/j.issn.2409-5680.2016.02.35

Cited by 8 publications

(17 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Because of their asymptomatic nature, the nasal BRVO is less diagnosed and reported. These ndings are in concordance with the 2,3,9,10,12,18,[25][26][27]30 result from many other similar studies. In CRVO, 50% (9/18) of the patients were aged less than 60 years.…”

Section: Resultssupporting

confidence: 93%

See 1 more Smart Citation

Demographic Profile of Patients With Retinal Vein Occlusion-an Observational Study

Hegde¹,

Dharwadkar³

et al. 2020

ijsr

View full text Add to dashboard Cite

BACKGROUND:Retinal Vein Occlusion(RVO) is a multifactorial, with many systemic and ocular risk factors.The incidence of RVO has increased with increased life expectancy and increased incidence of risk factors. AIM:This study was done to determine the demographic characteristics and risk factors in a tertiary care hospital in South India. METHODS:100 consecutive newly diagnosed cases of RVO were included in the study. A detailed history, complete ophthalmic examination and systemic evaluation was done. RESULTS: The majority of the patients were aged more than 60 years(55%) with male preponderance(54%).The study also found that RVO was strongly associated with increasing age.Hypertension,dyslipidemia,diabetes mellitus,smoking and hyperhomocysteinemia were important systemic risk factors.Glaucoma was an important ocular risk factor.BRVO is the most common type of RVO. CONCLUSION:RVO is associated with many systemic and ocular diseases.Identifying and managing these risk factors help in preventing a second attack in either eye and thereby the visual morbidity.

show abstract

Section: Resultssupporting

confidence: 93%

“…phlebitis. In keeping with ndings from similar previous studies, it 1,4,6,10,12,16,19,26 was found that the prevalence of RVO increased with age.…”

Section: Resultssupporting

confidence: 89%

Demographic Profile of Patients With Retinal Vein Occlusion-an Observational Study

Hegde¹,

Dharwadkar³

et al. 2020

ijsr

View full text Add to dashboard Cite

show abstract

“…In the BRVO subgroup, a significant (p < 0.05) reduction in the proportion of patients having IRF or SRF from baseline to weeks 4,8 (Fig. 6).…”

Section: Intraretinal and Subretinal Fluidmentioning

confidence: 93%

“…occlusion, the most frequently occurring types are branch RVO (BRVO), defined as occlusion of a branch of the retinal vein system, and central RVO (CRVO), defined as occlusion located in the central retinal vein [4,5].…”

Section: Introductionmentioning

confidence: 99%

“…It can cause severe vision loss through macular edema, retinal neovascularization, and retinal detachment [11]. Arterial stiffness is the main pathogenic mechanism for the development of BRVO, which can cause venous compression in the common adventitial sheath [4,7]. Increasing age, concomitant cardiovascular diseases, smoking, and hypertension are the major risk factors for BRVO [12].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Real-Life Clinical Effectiveness of Razumab® (the World’s First Biosimilar of Ranibizumab) in Retinal Vein Occlusion: A Subgroup Analysis of the Pooled Retrospective RE-ENACT Study

Sharma¹,

Khan²,

Chaturvedi³

2018

Ophthalmologica

View full text Add to dashboard Cite

Background: This subgroup analysis of the RE-ENACT study evaluates the effectiveness of Razumab® (the world’s first biosimilar of ranibizumab by Intas Pharmaceuticals Ltd.) in Indian patients with retinal vein occlusion (RVO). Methods: The data on patients with RVO who had received ≥3 injections of Razumab® between January and August 2016 were analyzed. Endpoints were: improvement in best corrected visual acuity (BCVA), and a decrease in central macular thickness (CMT), intraretinal fluid (IRF), and subretinal fluid (SRF) from baseline at weeks 4, 8, and 12. Results: Of 160 patients, the majority (61.87%) were men. The mean (±SE) BCVA improved from baseline (0.76 ± 0.04) to week 4 (0.73 ± 0.03; p = 0.0656), which attained significance at week 8 (0.55 ± 0.02; p < 0.0001) and week 12 (0.47 ± 0.02; p < 0.0001). The mean (±SE) CMT significantly decreased from baseline (447.60 ± 10.91 μm) to week 4 (431.84 ± 10.92 μm; p = 0.0028), week 8 (339.28 ± 8.12 μm; p < 0.0001), and week 12 (298.23 ± 6.68 μm; p < 0.0001). The proportion of patients with IRF and SRF significantly (p < 0.0001) decreased from baseline to weeks 4, 8, and 12 (IRF: from 70.63 to 45.63, 39.38, and 30.00%, respectively; SRF: from 65.63 to 37.50, 28.13, and 24.38%, respectively). A subgroup analysis of branch RVO and central RVO showed similar results. No new safety concerns were observed. Conclusion: Razumab® (biosimilar of ranibizumab) effectively improved visual acuity and disease outcomes in patients with RVO in a real-world setting with no new safety concerns.

show abstract

A Multicenter, Retrospective Study (RE-ENACT 2) on Razumab™ (World's First Biosimilar Ranibizumab) in Retinal Vein Occlusion

2020

View full text Add to dashboard Cite

Purpose The REal life assessmENt of safety And effeCTiveness of Razumab 2 (RE-ENACT 2) study evaluated the long-term effectiveness of biosimilar ranibizumab. We present the subgroup analysis of patients with retinal vein occlusion (RVO). Methods Data of patients who received pro re nata (PRN) biosimilar ranibizumab (November 2015 to December 2018, 17 centers) were analyzed. Endpoints were change from baseline in best corrected visual acuity (BCVA, Snellen’s/logMAR), central subfield thickness (CSFT), intraocular pressure (IOP), and proportions of patients having intraretinal fluid (IRF) and subretinal fluid (SRF) at weeks 4, 8, 12, 16, 20, 24, 30, 36, and 48. Results Of 101 patients, 48.51% were men, and the majority (79.21%) were treatment naïve and had received 3 (range 1–5) injections (53.5%). Significant improvements ( P < 0.05) were observed from baseline to all timepoints for BCVA [baseline, 0.89 ± 0.06 ( n = 94); week 48, 0.41 ± 0.08 ( n = 14)] and CSFT [baseline, 527.58 ± 19.9 ( n = 85); week 48, 307.47 ± 16.4 ( n = 15)]. Changes in IOP (mmHg) were non-significant [baseline, 15.38 ± 0.4 ( n = 94); week 48, 13.94 ± 0.6 ( n = 16); P = 0.5575). Proportions of patients having IRF [baseline, 71.3% ( n = 84) vs week 48, 0% ( n = 15)] and SRF [baseline, 52.5% ( n = 83) vs week 48, 0% ( n = 15)] were decreased. Similar results for BCVA, CSFT, IOP, IRF, and SRF were observed for BRVO and CRVO subgroups. There were no new safety concerns. Conclusions Biosimilar ranibizumab demonstrated improvements in visual acuity and disease outcomes up to 48 weeks in patients with RVO without any new safety concerns. Electronic supplementary material The online version of this article (10.1007/s40123-020-00277-3) contains supplementary material, which is available to authorized users.

show abstract

Definition and Classification of Retinal Vein Occlusion

Cited by 8 publications

References 16 publications

Demographic Profile of Patients With Retinal Vein Occlusion-an Observational Study

Demographic Profile of Patients With Retinal Vein Occlusion-an Observational Study

Real-Life Clinical Effectiveness of Razumab® (the World’s First Biosimilar of Ranibizumab) in Retinal Vein Occlusion: A Subgroup Analysis of the Pooled Retrospective RE-ENACT Study

A Multicenter, Retrospective Study (RE-ENACT 2) on Razumab™ (World's First Biosimilar Ranibizumab) in Retinal Vein Occlusion

Contact Info

Product

Resources

About